Why ketamine

Lisa Coles; Eric S. Rosenthal; Thomas P. Bleck; Jordan Elm; Shahriar Zehtabchi; James Chamberlain; James Cloyd; Shlomo Shinnar; Robert Silbergleit; Jaideep Kapur

doi:10.1016/j.yebeh.2022.109066

Why ketamine

Lisa Coles, Eric S. Rosenthal, Thomas P. Bleck, Jordan Elm, Shahriar Zehtabchi, James Chamberlain, James Cloyd, Shlomo Shinnar, Robert Silbergleit, Jaideep Kapur

Neurology

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

We present the rationale for testing ketamine as an add-on therapy for treating benzodiazepine refractory (established) status epilepticus. In animal studies, ketamine terminates benzodiazepine refractory status epilepticus by interfering with the pathophysiological mechanisms and is a neuroprotectant. Ketamine does not suppress respiration when used for sedation and anesthesia. A Series of reports suggest that ketamine can help terminate refractory and super refractory status epilepticus. We propose to use 1 or 3 mg/Kg ketamine intravenously based on animal-to-human conversion and pharmacokinetic studies. This paper was presented at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in September 2022.

Original language	English (US)
Article number	109066
Journal	Epilepsy and Behavior
Volume	141
DOIs	https://doi.org/10.1016/j.yebeh.2022.109066
State	Published - Apr 2023

Keywords

Established status epilepticus
NMDA receptor
Neuroprotection
Pharmacokinetics

ASJC Scopus subject areas

Neurology
Clinical Neurology
Behavioral Neuroscience

Access to Document

10.1016/j.yebeh.2022.109066

Cite this

@article{d75bf828adec430993d2b4907f27d9f8,

title = "Why ketamine",

abstract = "We present the rationale for testing ketamine as an add-on therapy for treating benzodiazepine refractory (established) status epilepticus. In animal studies, ketamine terminates benzodiazepine refractory status epilepticus by interfering with the pathophysiological mechanisms and is a neuroprotectant. Ketamine does not suppress respiration when used for sedation and anesthesia. A Series of reports suggest that ketamine can help terminate refractory and super refractory status epilepticus. We propose to use 1 or 3 mg/Kg ketamine intravenously based on animal-to-human conversion and pharmacokinetic studies. This paper was presented at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in September 2022.",

keywords = "Established status epilepticus, NMDA receptor, Neuroprotection, Pharmacokinetics",

author = "Lisa Coles and Rosenthal, {Eric S.} and Bleck, {Thomas P.} and Jordan Elm and Shahriar Zehtabchi and James Chamberlain and James Cloyd and Shlomo Shinnar and Robert Silbergleit and Jaideep Kapur",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2023",

month = apr,

doi = "10.1016/j.yebeh.2022.109066",

language = "English (US)",

volume = "141",

journal = "Epilepsy and Behavior",

issn = "1525-5050",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Why ketamine

AU - Coles, Lisa

AU - Rosenthal, Eric S.

AU - Bleck, Thomas P.

AU - Elm, Jordan

AU - Zehtabchi, Shahriar

AU - Chamberlain, James

AU - Cloyd, James

AU - Shinnar, Shlomo

AU - Silbergleit, Robert

AU - Kapur, Jaideep

PY - 2023/4

Y1 - 2023/4

N2 - We present the rationale for testing ketamine as an add-on therapy for treating benzodiazepine refractory (established) status epilepticus. In animal studies, ketamine terminates benzodiazepine refractory status epilepticus by interfering with the pathophysiological mechanisms and is a neuroprotectant. Ketamine does not suppress respiration when used for sedation and anesthesia. A Series of reports suggest that ketamine can help terminate refractory and super refractory status epilepticus. We propose to use 1 or 3 mg/Kg ketamine intravenously based on animal-to-human conversion and pharmacokinetic studies. This paper was presented at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in September 2022.

AB - We present the rationale for testing ketamine as an add-on therapy for treating benzodiazepine refractory (established) status epilepticus. In animal studies, ketamine terminates benzodiazepine refractory status epilepticus by interfering with the pathophysiological mechanisms and is a neuroprotectant. Ketamine does not suppress respiration when used for sedation and anesthesia. A Series of reports suggest that ketamine can help terminate refractory and super refractory status epilepticus. We propose to use 1 or 3 mg/Kg ketamine intravenously based on animal-to-human conversion and pharmacokinetic studies. This paper was presented at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in September 2022.

KW - Established status epilepticus

KW - NMDA receptor

KW - Neuroprotection

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85149693800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149693800&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2022.109066

DO - 10.1016/j.yebeh.2022.109066

M3 - Review article

C2 - 36609129

AN - SCOPUS:85149693800

SN - 1525-5050

VL - 141

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

M1 - 109066

ER -

Why ketamine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this